Adaptive BiotechnologiesADPT +2.10%67 Days Inventory is 51.28 as of Mar. 2026, which is 54% below its 10-year median of 111.55. GuruFocus rates ADPT with a GF Score™ of 67/100 and a GF Value™ of $10.06 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 176 Medical Diagnostics & Research companies, Adaptive Biotechnologies ranks better than 63.07% on this metric.
The historical rank and industry rank for Adaptive Biotechnologies's Days Inventory or its related term are showing as below:
ADPT'
s Days Inventory Range Over the Past 10 Years
Min: 46.7 Med: 111.55 Max: 187.38
Current: 47.99
During the past 9 years, Adaptive Biotechnologies's highest Days Inventory was 187.38. The lowest was 46.70. And the median was 111.55.
ADPT's Days Inventory is ranked better than 63.07% of 176
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.88
vs ADPT: 47.99
Inventory Turnover measures how fast the company turns over its inventory within a year.
Adaptive Biotechnologies's Inventory Turnover for the
three
months ended in Mar. 2026 was 1.78.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Adaptive Biotechnologies's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.15.
Adaptive Biotechnologies (NAS:ADPT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Adaptive Biotechnologies's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Adaptive Biotechnologies's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Adaptive Biotechnologies Days Inventory Related Terms
Adaptive Biotechnologies Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADPT vs GRAL, WGS, RDNT: Days Inventory Comparison
For the Diagnostics & Research subindustry, Adaptive Biotechnologies's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's Days Inventory distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies (ADPT) has a Days Inventory of 51.28 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Adaptive Biotechnologies and its competitors. This is 54% below median its historical median of 111.55. Over the past decade, Adaptive Biotechnologies' Days Inventory has ranged from 46.70 to 187.38. According to the industry distribution chart, Adaptive Biotechnologies ranks #65 out of 176 companies in the Medical Diagnostics & Research industry, placing it in the top 36.9%.
Is Adaptive Biotechnologies' Days Inventory too high?
Adaptive Biotechnologies' current Days Inventory of 51.28 is 54% below median its 10-year median of 111.55. Over the past 10 years, this metric has ranged from a low of 46.70 to a high of 187.38. The Medical Diagnostics & Research industry median Days Inventory is 68.88. Adaptive Biotechnologies' value of 51.28 is 25.6% below this industry median. Based on the distribution chart, Adaptive Biotechnologies ranks #65 out of 176 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Adaptive Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Days Inventory compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #65 out of 176 companies for Days Inventory. This puts Adaptive Biotechnologies in the upper half of its industry. The industry median Days Inventory is 68.88. Adaptive Biotechnologies' value of 51.28 is 25.6% below this benchmark. Historically, Adaptive Biotechnologies' own Days Inventory has ranged from 46.70 to 187.38 over the past decade. While the company's 10-year median is 111.55 vs. the industry median of 68.88, Adaptive Biotechnologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 68.88, based on 176 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adaptive Biotechnologies's current Days Inventory of 51.28 is 25.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Adaptive Biotechnologies and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 68.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptive Biotechnologies's current Days Inventory is 51.28, which is 54% below median its own 10-year median of 111.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.06, compared to a current price of $21.40 — trading 112.7% above its estimated fair value. The current Days Inventory is 51.28, which is 54% below median its 10-year median of 111.55 and 25.6% below the Medical Diagnostics & Research industry median of 68.88. Adaptive Biotechnologies' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Days Inventory is 51.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?
Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued.
The current stock price of $21.40 is trading 112.7% above its estimated GF Value™ of $10.06.
GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.
Key valuation signals for ADPT:
Days Inventory: 51.28 (54% below median its 10-year median of 111.55)
GF Value™: $10.06 vs. price of $21.40 (112.7% above fair value)
Industry Position: 25.6% below the Medical Diagnostics & Research median (#65 of 176)
No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
67GF Score
Get the complete analysis for ADPT
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADPT has been successfully added to your 
